Compared to anti-PD1 or c-Met inhibitors alone, combined treatment of c-Met inhibitors with anti-PD-1 increased tumor-infiltrating CD8+ T cells, decreased tumor growth, and prolonged survival of such mice [42]. Here, CD8A is linked to neoplasm.